Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2027

Conditions
Esophageal Cancer
Interventions
RADIATION

Involved field irradiation

Involved field irradiation; intensity-modulated radiation therapy

RADIATION

Elective field irradiation

Elective field irradiation; intensity-modulated radiation therapy

DRUG

Paclitaxel

Paclitaxel 135-150mg/m2, d1, every 3 weeks

DRUG

Platinum

for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;

DRUG

PEG-rhG-CSF

PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy

Trial Locations (1)

100021

RECRUITING

Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing

All Listed Sponsors
collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Anyang Tumor Hospital

OTHER

collaborator

Fujian Cancer Hospital

OTHER_GOV

collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Hebei Medical University Fourth Hospital

OTHER

lead

Chinese Academy of Medical Sciences

OTHER